COMPANY

Delcath

HQ: Queensbury, NY source · delcath.com ↗

Location: Queensbury, NY · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Ocular Melanoma Intrahepatic Cholangiocarcinoma Uveal Melanoma Refractory Metastatic Colorectal Cancer Metastatic Breast Cancer in the Liver Metastatic Ocular Melanoma Metastatic Uveal Melanoma Hepatocellular Carcinoma Bile Duct Cancer Intraocular Melanoma Melanoma (Skin) Hepatic Malignant Neoplasm Primary Non-Resectable Metastatic Liver Cancer Cutaneous Melanoma Melphalan/HDS

11Trials (company is sponsor)

Timeline

Jan 29, 2026 Trial start Phase 2: Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in source ↗
Aug 5, 2025 Trial start Phase 2: Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in source ↗
Jun 10, 2022 Trial start Phase 3: An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma source ↗
Apr 10, 2018 Trial start Phase 2/Phase 3: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma source ↗
Feb 1, 2016 Trial start Phase 3: Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma source ↗
Jan 14, 2016 Trial start —: Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy source ↗
2014-10 Trial start Phase 2: Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC source ↗
2014-06 Trial start Phase 2: Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma source ↗
2006-02 Trial start Phase 3: Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma source ↗
2004-09 Trial start Phase 2: Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 2 · Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients · NCT06607458
2029-05 (ESTIMATED) · Phase 2 · Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients · NCT06875128

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT02678572	Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma	Phase 3	Completed	Feb 1, 2016	May 18, 2023 (actual)
NCT06607458	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease	Phase 2	Recruiting	Aug 5, 2025	2026-12 (estimated)
NCT06875128	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease	Phase 2	Recruiting	Jan 29, 2026	2029-05 (estimated)
NCT05022901	An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma	Phase 3	Active, not recruiting	Jun 10, 2022	Mar 1, 2024 (estimated)
NCT02415036	Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma	Phase 2	Terminated	2014-06	2018-10 (actual)
NCT03086993	Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma	Phase 2/Phase 3	Unknown status (ClinicalTrials.gov)	Apr 10, 2018	2023-01 (estimated)
NCT00324727	Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma	Phase 3	Completed	2006-02	2012-08 (actual)
NCT03266042	Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy	Not listed	Unknown status (ClinicalTrials.gov)	Jan 14, 2016	2020-01 (estimated)
NCT02406508	Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC	Phase 2	Withdrawn	2014-10	2017-12 (actual)
NCT01728051	Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver	Not listed	No longer available	Not listed	Not listed
NCT00096083	Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer	Phase 2	Completed	2004-09	2012-08 (actual)